MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance, leading to neuronal hyperpolarization and central nervous system depression.
| Metabolism | Hepatic via CYP3A4 oxidation; primary metabolite is α-hydroxymidazolam (active). |
| Excretion | Renal: ~80% as metabolites (primarily 1-hydroxymidazolam glucuronide), <1% unchanged; biliary/fecal: ~2-10% |
| Half-life | 2-6 hours (prolonged in elderly, obesity, hepatic impairment, or critical illness; up to 12 hours in ICU patients) |
| Protein binding | 96-98% bound to albumin |
| Volume of Distribution | 1-3 L/kg (increased in obesity, decreased in elderly or hypovolemia) |
| Bioavailability | Oral: ~40% (range 30-50%, extensive first-pass); IM: ~90%; intranasal: ~50-80% |
| Onset of Action | IV: 1-3 minutes; IM: 5-15 minutes; intranasal: 10-15 minutes; oral: 15-30 minutes |
| Duration of Action | IV: 2-6 hours (sedation); IM: 2-6 hours; oral: 3-6 hours (context-dependent; prolonged with continuous infusion or in hepatic/renal impairment) |
Initial: 0.5-2 mg IV over 2-3 min; titrate by 0.5-1 mg increments q2-3min as needed; usual total 2.5-5 mg. Continuous infusion: 0.02-0.1 mg/kg/hr IV (1-7 mg/hr). Intranasal: 0.2-0.3 mg/kg (max 15 mg).
| Dosage form | SOLUTION |
| Renal impairment | GFR 10-50 mL/min: decrease dose by 50% and monitor for prolonged sedation. GFR <10 mL/min: avoid or use extreme caution; reduce dose by 75%. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 30-50% and monitor. Child-Pugh C: reduce dose by 50-75%; consider alternative agent. |
| Pediatric use | IV sedation: 0.05-0.1 mg/kg over 2-3 min (max 2 mg); may repeat q2-3min (total up to 0.2 mg/kg). Intranasal: 0.2-0.3 mg/kg (max 10 mg). Oral: 0.25-0.5 mg/kg (max 20 mg) 30-45 min pre-procedure. |
| Geriatric use | Initial dose reduction by 30-50% (e.g., 0.5-1 mg IV slow); slower titration; monitor for hypotension and respiratory depression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Midazolam is excreted into breast milk in small amounts; M/P ratio is approximately 0.15. Limited data; use caution, especially with repeated doses. Monitor infant for sedation and feeding difficulties. |
| Teratogenic Risk | First trimester: Inadequate human data; animal studies show increased fetal loss and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal withdrawal (floppy infant syndrome) and respiratory depression if used near term. Avoid prolonged or high-dose use. |
■ FDA Black Box Warning
Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required.
| Common Effects | fluid replacement |
| Serious Effects |
["Acute narrow-angle glaucoma","Known hypersensitivity to benzodiazepines","If used for anesthesia in preterm infants (risk of cardiovascular collapse)","Concomitant use with saquinavir (CYP3A4 interaction)","Severe respiratory insufficiency (relative)","Myasthenia gravis (relative, caution)"]
| Precautions | ["Respiratory depression: monitor oxygen saturation and respiratory function, especially in elderly or debilitated patients","Hypotension: risk in hemodynamically compromised patients","Paradoxical reactions: restlessness, agitation, hostility (discontinue drug)","Physical dependence and withdrawal: abrupt discontinuation may cause seizures and withdrawal syndrome","Use in pregnancy: risk of congenital malformations (reported in first trimester) and neonatal withdrawal (chronic use in later trimesters)","Renal or hepatic impairment: reduce dose and monitor for prolonged sedation","Myasthenia gravis: may worsen muscle weakness","Severe COPD or sleep apnea: increased risk of respiratory depression","Intra-arterial injection: may cause arteriospasm and gangrene (avoid)","Geriatric use: increased sensitivity, lower doses recommended"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory rate, oxygen saturation, and sedation level continuously during administration. Fetal heart rate monitoring recommended if used in labor. Neonatal monitoring for respiratory depression and hypotonia if used near delivery. |
| Fertility Effects | No human data on fertility effects. Animal studies show no significant impact on fertility at clinically relevant doses. |